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a b s t r a c t
Background/aims: Virological factors associated with hepatitis B virus reactivation (HBV-R), following
chemotherapy for cancer in hepatitis B surface antigen (HBsAg)-negative patients, are not well known.
Materials and methods: HBV strains from 16 patients presenting HBV-R following chemotherapy were
studied and compared to those obtained from 51 HBV chronically-infected patients.
Results: HBsAg variability was signiﬁcantly increased within the major hydrophilic region, the a
determinant and the C-terminal region. Amino acid substitutions were more frequently found in HBV-
R patients as compared to controls at 17 and 11 positions within HBsAg and HBV-RT, respectively. This
resulted in atypical serological testing in 56% of patients and detection of resistance mutation to
nucleoside analogs in 12.5%.
Conclusion: HBsAg and HBV-RT mutations are frequently encountered in patients with HBV-R, resulting
in atypical serological testing and emergence of HBV strains resistant to nucleos(t)ides analogs.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Hepatitis B virus (HBV) reactivation is a rising concern in
patients undergoing chemotherapy for cancer. Indeed, an increas-
ing number of therapeutic agents used are likely to interfere with
the natural course of HBV infection. Thus, HBV reactivation (HBV-
R) has been described with the use of biotherapies such as
monoclonal antibodies like rituximab (Lalazar et al., 2007; Ling
et al., 2013). In this context, recommendations have been proposed
for the management of HBV-infected patients necessitating
chemotherapy for cancer and preventive treatment of hepatitis B
surface antigen (HBsAg)-positive patients with nucleos(t)ides
analogs is recommended (European Association For The Study Of
The Liver, 2012). The risk of HBV reactivation is much lower in
patients negative for HBsAg but positive for anti-hepatitis B core
antibody (HBcAb) and the management of these patients is still
debated (Hsu et al., 2014).
Clinical factors associated with HBV-R following chemotherapy
in initially HBsAg-negative patients have been previously studied.
Indeed, male sex, type of cancer including hematological or breast
cancer, intensity of therapy, rituximab use and a low anti-HBsAb
level at baseline have been reported to be associated with an
increased risk for HBV-R (Hsu et al., 2014; Yeo et al., 2009; Seto
et al., 2014; Mikulska et al., 2014; Kim and Kim, 2014). Speciﬁc
HBV genotypic patterns might also be found in this clinical setting.
Indeed, mutations in the basal core promoter conferring higher
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replication capacity have been reported in fulminant forms of
HBV-R (Hsu et al., 2014; Borentain et al., 2010; Alexopoulou et al.,
2006; Yeo et al., 2000; Gérolami et al., 2005), and mutations
within HBsAg have been described in HBsAg-negative-patients
presenting HBV reactivation, in some cases in association with
rituximab administration (Hsu et al., 2014; Seto et al., 2014;
Mikulska et al., 2014; Kim and Kim, 2014; Borentain et al., 2010;
Westhoff et al., 2003; Sugauchi et al., 2011). However, HBV
genotypic characteristics have not been extensively studied in
patients undergoing HBV-R and the actual frequency of these
genotypic patterns as well as their consequences in the manage-
ment of these patients are not known.
In the present work we systematically studied genotypic
patterns of HBV collected from 16 consecutive HBsAg-negative
patients who developed HBV-R following chemotherapy in our
institution. All these patients were HBsAg-negative but positive for
anti-HBc with or without anti-HBsAb at time of initiation of CT. We
show that in these patients, mutations within core/precore regions
are systematically encountered in association with an increased
variability within HBsAg and HBV reverse transcriptase (HBVrt).
The emergence of such HBV mutants in this clinical context may
have important implication in the management of these patients.
Statistical analysis
The data were analyzed using SPSS v9.0 software program.
Pearson’s chi-square test and Fisher’s exact test were used for
comparison of categorical variables, and the Student’s t-test was
used for comparison of continuous variables. Statistical signiﬁ-
cance was set at the 0.05 level.
Results
HBV serological/molecular status before initiation of chemotherapy
and at time of reactivation
Results of serological patterns at time of diagnosis of reactiva-
tion and before chemotherapy initiation are presented in Table 2.
HBV status before chemotherapy initiation
Before chemotherapy initiation, all 16 patients were HBsAg-
negative. None of these patients received prophylactic treatment.
Anti-HBsAb could be detected in 10 of 15 (66 %) patients tested
at baseline (mean titer, 114 IU/L (range, 14–897 IU/L)). HBV DNA
determination could be retrospectively performed before che-
motherapy in seven patients. HBV DNA was detected in 5 of them
(71%) (Table 2). In one patient (pt 11), HBsAg was retrospectively
found positive before chemotherapy using a second test (Vidas).
HBV DNA determination could not be done before chemotherapy
in this patient.
HBV status at time of reactivation
HBV reactivation occurred during chemotherapy in 5/16 patient,
and in the 11/16 remaining patients between 3 and 12 months
following the end of chemotherapy (mean 5.5 months). At time of
reactivation, diagnosis of HBV reactivation was made difﬁcult by
atypical serological testing in 5 patients (31%; pts 2, 6, 10, 12, 16)
(Table 2). Thus, at time of reactivation, HBsAg was found negative in
three patients (pts 2, 6, 10) and HBsAg and anti-HBsAb were
concurrently detected in two other patients (pts 12, 16). In patient
2, HBsAg could be retrospectively detected using the Vidas assay
instead of the Axsym assay. Patients 6 and 10 were found negative
for HBsAg using both Axsym and Vidas tests, while patient 10
presented with a serological pattern indicating cured HBV infection
(HBsAg-negativity, anti-HBsAb-positivity (535 IU/L)). Finally, in all
cases, diagnosis of HBV reactivation was deﬁnitively set by HBV
DNA detection.
Overall, pitfalls in the serological diagnosis of HBV infection,
before chemotherapy and/or during the course of anticancer
therapy, could be demonstrated in 9 out of 16 patients (56%) (pts
2, 5, 6, 8, 10, 11, 12, 14, 16). In these 9 patients, systematic HBV DNA
determination before CT and during follow-up might have led to
introduce earlier anti-HBV therapy and possibly to modify the
course of HBV reactivation. Indeed, one of these patients (pt 5),
who was retrospectively found HBV DNA positive before CT, died
from fulminant hepatic failure despite introduction of lamivudine
therapy at time of clinically-symptomatic HBV reactivation.
Outcome of patients following HBV reactivation
From 2002 through 2006, all patients received after the
diagnosis of HBV reactivation either lamivudine (n¼7), lamivudine
plus adefovir (n¼1) or no treatment (n¼1). From 2006 through
2011, all patients received either entecavir (n¼4) or tenofovir
(n¼3) as ﬁrst line treatment. Four patients (25%) died from
fulminant hepatic failure (pts 1, 3, 5 and 9). All of these patients
were taken in charge before 2006 and had received either
lamivudine (n¼3) or no treatment (n¼1), whereas no HBV-
related death was observed during the 2006–2010 period
(p¼0.04).
Genotypic patterns of HBV from patients with reactivation
To identify speciﬁc HBV genotypic patterns associated with
HBV reactivation, HBV sequences obtained from the 16 patients
with HBV reactivation were compared with those obtained from
the 51 newly diagnosed chronic HBV-carriers.
Genotype, precore and core promoter mutations
Patients presenting HBV reactivation were infected with geno-
types D (n¼13), C (n¼2) and A (n¼1). Non-A genotypes were
signiﬁcantly more frequent in HBV-R patients versus controls (94%
vs. 49%; p¼0.012).
Mutation A1762C within the core promoter region was detected
in two patients infected with genotype D HBV (Table 3); this later
mutationwas never found in HBV sequences obtained from controls
(p¼0.068). In addition, precore mutation G1896A was detected in
Table 1
Clinical and virological characteristics of patients with HBV reactivation and
controls.
Patients with HBV reactivation at
time of reactivation, N¼16
Controls,
N¼123
Median age (years) 65 43
Gender (M/F) 15/1 79/44
HBV DNA detection 16/16 51/123
HBV DNA quantiﬁcation
410000 IU/mL 11/16 16/94
o200 IU/mL 0/16 50/94
HBV genotype
A 1/16 26/51
B 0/16 0/51
C 2/16 2/51
D 13/16 18/51
E 0/16 5/51
Non A 15/16 25/51
P. Colson et al. / Virology 484 (2015) 354–363 355
HBV collected from 7 out of 16 patients and mutation G1899A was
detected in HBV from 6 patients. These frequencies were not
signiﬁcantly different as compared to those observed for control-
patients. Interestingly mutation G1899A, previously reported in
HBV-related fulminant hepatic failure, was found in 3 out of
4 patients (75%) who died as compared to 3 out of 12 patients
(25%) who survived (p¼0.12) (Alexopoulou et al., 2006).
Amino acid variability within HBsAg
Amino acid variability within HBsAg is represented in Table 4
and Fig. 1. The mean number of substitutions/100 amino acids was
signiﬁcantly higher in the «reactivation» group as compared to the
reference group within HBsAg major hydrophilic region (MHR)
(7.4 vs. 2.1; po10–3), its «a» determinant (11.5 vs. 2.5; p¼0.003),
and regions 1 (8.3 vs. 2.7; p¼1.7e–3) and 3 (12.5 vs. 3.1; p¼0.012)
within the HBsAg MHR (Table 3). Signiﬁcant differences in amino
acid variability were also found between HBV-R patients and
controls when considering only genotype D sequences from both
groups for the MHR (7.4 vs. 2.1; po1e–3) including the “a”
determinant (11.7 vs. 3.5; po1e–3), and regions 1 (8.1 vs. 2.6;
p¼0.010) and 3 (12.8 vs. 5.1; p¼0.049) within HBsAg MHR.
Mutations at positions s134 and s175 were the most frequently
encountered from patients presenting HBV reactivation, being
present in at least 6 of 16 HBV-R patients. Amino acid substitutions
at positions s144 (D144A/V) or s145 (G145R/A) within the «a»
determinant and well-known to be associated with altered anti-
genicity of the S protein (http://hbv.geno2pheno.org/index.php)
(Carman, 1997; Cooreman et al., 2001; Gerlich, 2006), were found
in HBsAg sequences from 7 of 16 patients (44%) with HBV
reactivation. Thus, these mutations were signiﬁcantly more fre-
quently found in the «reactivation» group than in the reference
group (25% vs. 0% (p¼0.002) and 25% vs. 2% (p¼0.01), respec-
tively). Overall, amino acid substitutions were signiﬁcantly more
frequent at 16 positions within HBsAg in the «reactivation» group
as compared to the control group (po0.05; Figs. 1 and 2). In
addition, at time of reactivation, all 16 patients presented at least
one amino acid substitution within HBsAg among substitutions
that were more frequently found in HBV-R than in controls (Fig. 1).
In one patient, a deletion corresponding to amino acid 108–114
was found.
Most of HBsAg amino acid substitutions observed here at time
of HBV-R were previously reported and several were associated
with altered HBsAg immunoreactivity (http://hbv.geno2pheno.
org/index.php) (Carman, 1997; Cooreman et al., 2001; Gerlich,
2006; Niscola et al., 2005; Araujo et al., 2009; Weinberger et al.,
Table 2
Clinical and serological characteristics of patients at baseline and at time of reactivation.
Patient
no.
Year of
reactivation
Gender/
age
Type of
cancer
HBV status at baseline HBV status at time of reactivation Treatment Outcome
HBsAg HBsAb HBeAg HBV DNA HBsAg HBsAb HBeAg HBV DNA (IU/mL)
1 2002 F/76 MH Neg 28 N.a. N.a. Pos Neg Neg 6,963,350 LAM Death
2 2004 M/63 MM Neg 58 Neg Pos (27 IU/mL) Nega Neg Neg 42,150 LAMþADV Resolved
3 2005 M/70 NHL Neg Neg N.a. N.a. Pos Neg Pos 4110,000,000 LAM Death
4 2005 M/68 NHL Neg 31 N.a. N.a. Pos Neg Pos 113,490,000 LAM Resolved
5 2005 M/54 MM Neg 15 N.a. Pos (164 IU/
mL)
Pos Neg Neg 2790 LAM Death
6 2005 M/44 AL Neg Neg N.a. N.a. Neg Neg Neg 50,118 LAM Resolved
7 2005 M/67 NHL Neg 81 N.a. N.a. Pos Neg Neg 3981 LAM Resolved
8 2005 M/54 NHL Neg Neg N.a. Posb Pos Neg Neg 78,800,000 LAM Resolved
9 2006 M/65 NHL Neg Neg / N.a. Pos Neg Neg 81,000,000 None Death
10 2008 M/61 NHL Neg Neg N.a. Pos (30 IU/mL) Neg 535 Neg 5780 TDF Resolved
11 2007 M/48 NHL Nega Neg Neg N.a. Pos Neg Neg 4110,000,000 ETV Resolved
12 2009 M/59 NHL Neg 14 Neg Neg Pos Pos Neg 480,000 TDF Resolved
13 2009 M/79 NHL Neg 897 N.a. N.a. Pos Neg Neg 128,901 ETV Resolved
14 2009 M/72 LC Neg Neg N.a. Posb Pos Neg Pos 167,792 ETV Resolved
15 2010 M/65 MM Neg 594 N.a. Neg Pos Neg Pos 83,000,000 TDF Resolved
16 2010 M/66 CLL Neg NA N.a. N.a. Pos 154 Neg 278,535 ETV Resolved
Bold font indicates an atypical virological pattern.
a Negative result retrospectively found positive with another test.
b Not quantiﬁable.
Table 3
Core/precore mutations and genotype of HBV-R patients at time of reactivation.
Patients
1a 2 3a 4 5a 6 7 8 9a 10 11 12 13 14 15 16
Genotype A D D C D D C D D D D D D D D D
Core/precore positions Reference
1858 C T T T T T T T T T T C T C T T T
1896 G T A A G G A A A A G T A T G G G
1899 G G G A/G A A G G G A/G G G A G G G A
1762 A A A A/C A A A A C A A A A A A A A
1764 G G G G G G G G G G G G G G G G G
Bold font shows mutated positions.
a Patients who died following HBV-R.
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2000; Yong-Lin et al., 2012; Simon et al., 2013; Yao et al., 2013;
Pezzano et al., 2011; Baclig et al., 2014; Lee et al., 2005; Moradi
et al., 2012; Lin et al., 2013; Salpini et al., 2015). In contrast, two
substitutions N131A observed here in a patient whose serum
sample tested HBsAg-negative at time of HBV-R (pt 10) and
S136F (pt 5) were not, to our knowledge, previously described.
Moreover, additional N-linked glycosylation sites were detected
within HBsAg MHR from HBV of genotype D obtained from two
patients with HBV-R, due to amino acid substitutions T116N (in pt
3) and Y134N (pt 10), and the latter was associated with HBsAg
negativity at time of HBV-R. In HBV sequences from control
patients, an additional N-linked glycosylation site was detected
in two patients infected with HBV of genotype A in associa-
tion with amino acid substitution T131N and one patient infec-
ted with HBV of genotype D in association with amino acid
substitution M133T.
In 4 patients (pts 2, 8, 10 and 14), HBsAg sequences could be
compared before CT and at time of reactivation (Table 5). In one
patient (pt 8), although several HBsAg HBV mutants could be
detected before CT, a major HBsAg mutation at position 144 could
only be detected at time of reactivation. In the 3 other patients (pts
2, 10 and 14), HBV obtained before CT were almost identical to
those obtained at time of diagnosis of HBV reactivation, including
the presence of major HBsAg mutations in 2 case-patients (G145R
in patient 2 and D144A in patient 10).
Amino acid variability within HBV reverse transcriptase
Amino acid variability of HBV-RT is represented in Fig. 2.
Regions of RT overlapping the previously deﬁned sub-regions of
HBsAg were separately analyzed to appreciate the potential impact
of HBsAg variability on RT variability.
The mean number of substitution per 100 amino acids within
the RT region corresponding to the HBsAg “a” determinant was
higher in the «reactivation» group, although the difference did not
reach signiﬁcance (8 vs. 3.6; p¼0.12). We paid particular attention
to the RT region that overlaps the C terminal region of HBsAg and
spans sub-domains B, C and D of HBV RT, within which mutations
described as conferring resistance to antiviral drugs occur
(Locarnini and Bowden, 2010). In this RT region, the mean number
of substitution per 100 amino acids was not different between the
«reactivation» group and the control group (1.3 vs. 1.3).
Table 4
Number of substitutions per 100 amino acid positions within HBsAg (a) and overlapping regions of reverse transcriptase (b) for HBsAgþ/anti-HBsAbþ patients and controls.
a.
Regions of
HBsAg
Amino acid
positions
Substitutions per 100 amino acid positions within HBsAg7SD
All genotypes Genotypes D
HBV reactivation group
(n¼16)
Control group
(n¼51)
P HBV reactivation group
(n¼13)
Control group
(n¼18)
P
N-terminal
region
1–99 2.5 74.9 1.9 73.8 0.34 2.674.9 1.173.4 0.77
MHR (aa 100–
169)
100–169 7.478.2 2.173.2 1.4e–
6
7.478.4 2.174.7 0.9e–
5
“a” determinantn 125–146 11.5710.9 2.573.5 0.6e–
3
11.7710.7 3.576.7 0.4e–
3
Region 1 100–120 8.376.9 2.773.2 1.7e–
3
8.177.9 2.674.5 0.008
Region 2 122–123 9.474.4 6.979.7 11.575.4 2.873.9 0.21
Region 3 125–136 12.5711.3 3.1 74.0 0.012 12.8710.0 5.178.0 0.049
Region 4 140–146 9.8710.7 1.472.2 0.064 9.9712.3 0.872.1 0.078
Region 5 148–169 4.875.8 1.372.1 0.062 4.575.6 1.072.8 0.066
C terminal region 170–226 6.679.1 3.8 77.3 0.073 6.979.8 3.778.2 0.061
b.
N–terminal
region
1–99 1.675.2 1.376.1 0.71 1.675.2 0.974.0 0.29
MHR (aa 100–
169)
100–169 5.078.0 3.376.3 0.16 4.978.0 3.576.5 0.03
“a”
determinantnn
125–146 8.9710.7 4.177.4 0.09 8.9711.3 5.378.4 0.24
Region 1 100–120 6.877.9 6.377.9 0.84 6.276.7 5.877.3 0.85
Region 2 122–123 3.174.4 6.373.1 3.875.4 8.373.9
Region 3 125–136 9.4711.1 2.774.1 0.063 9.6711.9 4.678.1 0.24
Region 4 140–146 8.0710.7 6.5711.1 0.801 7.7710.9 6.379.3 0.800
Region 5 148–169 0.972.9 0.370.7 0.493 1.073.6 0.371.2 0.53
C terminal region 170–226 1.773.7 1.573.6 0.77 2.074.5 1.172.9 0.21
Amino acid variability was analyzed for HBV sequences from any genotype and, separately, from genotype D.
HBsAg, HBs antigen; anti-HBsAb, anti-HBs antibodies; aa, amino acid; MHR, major hydrophilic region; RT, reverse transcriptase; SD, standard deviation.
For analysis, HBsAg was divided into subregions corresponding to structural and/or functional domains: the N terminal region (amino acid 1–99), the major hydrophilic
region (MHR; amino acid 100–169) and the C terminal region (amino acid 170–226). The MHR includes ﬁve subregions: HBsAg subregion 1 (amino acid 100–120), HBsAg
subregion 2 (amino acid 121–123), HBsAg subregion 3 (amino acid 124–137), HBsAg subregion 4 (amino acid 138–147) and HBsAg subregion 5 (amino acid 148–169)
(Westhoff et al., 2003). The “a” determinant (amino acid 124–147) spans HBsAg subregions 3 and 4.
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Fig. 1. Amino acid variability in the hepatitis B surface antigen from patients with and without hepatitis B reactivation.
Amino acid variability was analyzed for HBV sequences from any genotype and, separately, from genotype D. Both amino acids are noted when two different amino acids are
harbored at the same position by reference sequences of the same genotype. Proportion of mutated sequences at a given position was calculated as follows: proportion of
sequences that do not harbor amino acid(s) found in HBV reference sequences of the same genotype. Amino acids harbored by HBV genotypes A, C, D from the NCBI HBV
genotyping reference panel (http://www.ncbi.nih.gov/projects/genotyping/view.cgi?db=2) are shown on the left side. For HBV reference sequences: only positions with
amino acid substitutions as compared to HBV reference sequences of same genotypes are shown; a dash means the absence of amino acid substitution. For HBV sequences
from patients: only positions with amino acid substitutions in HBsAg as compared to HBV reference sequences of corresponding genotype are shown; a dash means the
absence of amino acid substitution. P value is indicated by a boldface at positions where the proportion of sequences harboring mutations was signiﬁcantly higher from
patients with hepatitis B reactivation than from controls are marked with an asterisk; when wild-type and mutated amino acid(s) are concomitantly found at a given
position in bulk sequence, all these amino acids are indicated; indeed, our direct sequencing method allows the detection of mixed sequences from different HBV quasi-
species. Amino acid substitutions found in HBV sequences from patients with HBV reactivation and not from control patients are in a grey font and framed.
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Nonetheless, amino acid substitutions within HBV-RT were
more frequently found in the «reactivation» group than in the
control group at 11 different amino acid positions (rt9, rt16, rt54,
rt76, rt112, rt130, rt142, rt181, rt241, rt267 and rt319) including
positions rt181 and rt241 located within the D domain of HBV RT.
Amino acid substitution at position rt181, known to confer
resistance to lamivudine and adefovir, could be detected from
2 patients (pts 12 and 16) at time of reactivation, before introduc-
tion of any antiviral drugs. This substitution was never detected in
HBV from patients in the control group (p¼0.05). Moreover, amino
acid rt153Q, corresponding to s145R, was found in HBV from
5 patients. This amino acid substitution rtR153Q is known to
restore HBV replication of LAM resistant mutants (Carman, 1997).
Finally, a 12-nucleotide deletion within RT coding region
corresponding to amino acid positions 118–121 was found in 27%
of HBV clonal sequences from pt 10.
Discussion
In the present work, we show that speciﬁc genotypic HBV
patterns are found in patients presenting with HBV-R following
Fig. 2. Amino acid variability within HBsAg (a) or reverse transcriptase (b) of HBV sequences from patients with HBV reactivation (dark grey rods) or control patients (white
rods). Amino acid variability was considered the percentage of sequences that harbored at a given position another amino acid that the one found in HBV reference
sequences of the same genotype (found in the genotyping reference set of HBV sequences available on the NCBI Web site, http://www.ncbi.nih.gov/projects/genotyping/view.
cgi?db=2). Only variable positions (in HBV from either the case-patients or the control-patients, or from patients of both groups) are shown.
Table 5
HBsAg amino acid substitution before and at time of HBV reactivation in the four patients in whom HBV DNA could be sequenced before reactivation.
Patient
no.
HBsAg amino acid substitutions at positions
where variability was signiﬁcantly higher in
HBV from patients presenting reactivation
than from controls
Amino acid substitutions within HBsAg between sequences obtained before and at time of reactivation
Before reactivation At time of
reactivation
Before reactivation/at time of reactivation
2 M103M/I, S136S/Y, G145R,
S174N, L175L/S
S136/Y, G145R,
S174N, L175S
M/I103M, Y/S136Y, C/W137C, S/L175S, T/I226T
8 F8L, E164D, S193L D144D/V, L175L/S K/R24K, S/N31S, P/T67P, A118T, G/R130G, T140T/I, D144D/V, G/A159G, D164E, S/L167S, L175L/S, T181Q, G/
V182W, A186L, F187S, P189T, L193S, W/R196W, Y/C200Y, G/V202G, G/C206C, T/I207T, P211P/H, P/Q217P, F/
C220F
10 Y134N, D144A, E164G,
L175S
Y134N, D144A,
E164G, L175S
Q129P, G130E, L213S
14 E164V E164V None
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chemotherapy for cancer. We found that in the context of
chemotherapy, HBV-R involved more frequently non-A HBV geno-
types (mostly D genotypes) than genotype A viruses, although
genotype A is the most frequently found in our area (Tamalet et al.,
2006). This ﬁnding is congruent with the results from Salpini et al.
(2015) who recently reported that all 29 patients presenting HBV-
R were infected with HBV of genotype D, and it adds further data
to previously published results suggesting that speciﬁc clinical
outcomes of chronic hepatitis B might be associated with speciﬁc
HBV genotypes (Malmström et al., 2012; Lin and Kao, 2011). We
also observed a considerable frequency of core and/or precore
mutations in viruses from patients presenting HBV reactivation.
Thus, core/precore HBV mutants could be detected from all
patients. The high frequency of these mutants might simply reﬂect
the fact that most patients (86%) were infected with genotype D
HBV strains, which are known to favor the emergence of core/
precore mutants (Malmström et al., 2012). These data suggest that
core/precore mutants are likely either to promote HBV reactivation
or to be speciﬁcally selected during HBV reactivation. Emergence
of core/precore mutants has been previously reported in the
context of HBV reactivation (Alexopoulou et al., 2006; Gérolami
et al., 2005). Core/precore mutations have been described to
confer higher replicative capacity to HBV (Yeo et al., 2000; Ozasa
et al., 2006). In the absence of immune system pressure following
polychemotherapy, these HBV strains could therefore be more
likely to emerge as major strains. In addition, these viruses might
also be involved in the severe clinical outcome of HBV reactivation
(Sainokami et al., 2007). Indeed, mutation G1899A, previously
reported being associated with HBV-related fulminant hepatic
failure, was three-times more frequent in the present study in
HBV from patients who died from fulminant hepatic failure than
from those who survived (Sainokami et al., 2007).
An important result of the present work is the high frequency
of amino acid substitutions that could be detected within HBsAg in
HBV from patients with HBV reactivation.
Detection of HBsAg mutants has been described in up to 11% of
chronic HBV carriers in Asia and has been reported to be frequently
associated with different HBV clinical contexts including following
HBV vaccine immunization, nucleoside analog therapy or anti-HBsAg
immunoglobulin injection (see for review Alavian et al. (2013)). The
detection of such HBV mutants in the context of HBV-R has been
previously described in some case reports or series (Seto et al., 2014;
Alexopoulou et al., 2006; Westhoff et al., 2003). In the recent study
from Salpini et al., HBsAg substitutions were detected in 22 out of the
29 patients who developed HBV-R during immunosuppression, and
13 of these substitutions were signiﬁcantly more frequent in patients
presenting HBV-R than in controls. It has to be underlined that HBsAg
was positive in 10 of these 29 patients before immunosuppressive
treatment (Salpini et al., 2015). Noteworthy, in this study, prevalence
of HBsAg amino acid substitutions D144E and G145R known to
hamper HBsAg recognition by anti-HBsAb was 21% and 17% in
patients with HBV-R, respectively, being signiﬁcantly more frequent
than in control-patients. In addition, in the study from Seto et al.
(2014), substitution G145R was detected in one out of four patients in
whom HBsAg could be sequenced. We also previously reported the
detection of HBsAg amino acid substitutions in 7 patients presenting
with HBV reactivation from a cohort of 51 HBsAg-negative/anti-HBc-
positive patients who underwent chemotherapy for cancer (Borentain
et al., 2010). However, in this latter study, the small number of
patients and the absence of control group prevented from drawing
conclusion on the meaning of this ﬁnding. The present study,
extended to a larger group of 16 consecutive patients and a large
control group of chronic HBV carriers, strongly suggests that muta-
tions within HBsAg are systematically encountered in patients pre-
senting HBV reactivation. This ﬁnding has important clinical
implication because HBsAg HBV mutants have been associated with
false negativity of HBsAg serological testing as well as peculiar HBV
serological patterns such as the concurrent detection of HBsAg and
anti-HBsAb (Colson et al., 2007). Noteworthy, in the present study,
unusual HBV serological patterns were found in 5 patients (31%) at
time of reactivation. These confusing serological results may delay the
diagnosis and therefore the treatment of HBV reactivation. This is a
critical issue as HBV reactivation is a life threatening disease (25%
mortality rate in our study) and early treatment might be mandatory
to improve the prognosis. In view of the impaired performance of
HBV serological testing in these patients, HBV DNA detection should
be performed in patients presenting with acute hepatitis in a context
of chemotherapy for cancer, regardless of the results of HBV serology.
The signiﬁcance of the emergence of HBsAg HBV mutants in the
context of chemotherapy for cancer is unknown. We have pre-
viously reported that peculiar serological patterns such as
concurrent detection of HBsAg and antiHBs-Ab, associated with
HBsAg mutations, were frequently observed in immunocompro-
mized patients (Colson et al., 2007). Patients undergoing che-
motherapy for cancer, especially hematological cancer, or patients
undergoing speciﬁc therapies such as rituximab have impaired
immunity. In these patients, the decreased afﬁnity of anti-HBsAb
for mutated HBsAg might lower their protective effect and
decrease the overall control of HBV replication by the immune
system. In their recent study, Salpini et al. (2015) identiﬁed
additional N-linked glycosylation sites related to HBsAg mutations
within the major hydrophilic region that can mask immunogenic
epitopes. We detected such additional N-linked glycosylation sites
from two patients infected with HBV of genotype D. Therefore,
HBsAg mutated HBV strains might be positively selected following
immunosuppression in patients who have previously developed
efﬁcient humoral immune response against HBV.
Another explanation for the high frequency of HBsAg muta-
tions in HBV-R patients might be that chronic HBV carriers
harboring HBsAg mutations might have been misdiagnosed as
HBsAg-negative by serological testing at baseline. Indeed, it is
striking that detection of HBV DNA despite negative HBsAg testing
could be demonstrated in 5 out of the 7 patients tested at baseline,
while in another patient, HBsAg was retrospectively found positive
before chemotherapy initiation using a second serological assay. In
this view, our study also raises the question of the optimal HBV
monitoring that should be proposed to patients. To date, preven-
tive treatment of HBsAg-positive patients before chemotherapy is
recommended (European Association For The Study Of The Liver,
2012). Regarding HBsAg-negative patients, HBV monitoring,
including HBV DNA detection at time of HBV serological screening,
has been increasingly proposed in patients presenting with iso-
lated anti-HBcAb before chemotherapy (European Association For
The Study Of The Liver, 2012; Hwang and Lok, 2014). Thus, the risk
of HBV reactivation in isolated anti-HBcAb positive patients under-
going chemotherapy for lymphoma has been reported to be as
high as 25–30% (Hsu et al., 2014; Mikulska et al., 2014).
Recommendations for patients presenting with a serological
pattern of past “cured” HBV infection (as indicated by concurrent
detection of anti-HBc and anti-HBs antibodies) are still debated.
Indeed, the risk of HBV reactivation following chemotherapy is not
well known in these patients. In our previous study, 3 out of 56
patients (5.3%) positive for both anti-HBc and anti-HBs antibodies
developed HBV reactivation following chemotherapy. It is however
worthy to note that, in the present study, 8 of 15 tested patients
(56%) were positive for anti-HBsAb with a signiﬁcant titre (up to
897 IU/mL) at baseline.
In the recent study from Taiwan by Hsu et al. (2014), 53% of
lymphoma patients presenting HBV reactivation were antiHBsAb-
positive before chemotherapy initiation. The proportion of
antiHBsAb-positive patients at baseline was 68% in the study from
Seto et al. (2014) and 64% in the study from Mikulska et al. (2014).
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These ﬁndings suggest that in the context of chemotherapy for
cancer, detection of anti-HBsAb does not exclude the possibility of
low-level HBV replication and strongly support the use of HBV
DNA testing before chemotherapy in anti-HBcAb positive patients,
regardless the results of anti-HBsAb testing (Ferraro et al., 2009).
In this view, in our present study, two antiHBsAb positive patients,
out of the four tested, were retrospectively found positive for HBV
DNA testing before chemotherapy initiation.
Another important consequence of HBsAg variability is its
possible impact on HBV reverse transcriptase (Torresi et al.,
2002). We show that HBVrt from patients undergoing HBV
reactivation display an increased variability as compared to HBVrt
from newly diagnosed HBV-infected patients. Moreover, amino
acid substitution at position rt181 could be found in HBV strains
from 2 patients before any treatment. Substitution at this position
has been shown to confer resistance of HBV strains to lamivudine
as well as adefovir (Gerolami et al., 2006). Although most
published studies used lamivudine and lamivudine is still pro-
posed in the preemptive or prophylactic treatment of HBV reacti-
vation following chemotherapy (European Association For The
Study Of The Liver, 2012), the present data add further evidence
that the use of drugs with a high genetic barrier for resistance
(tenofovir and entecavir) should be favored in the clinical context
of HBV reactivation (Seto et al., 2014; Salpini et al., 2015; Colson et
al., 2008; Nakamoto et al., 2014; Kim et al., 2012; Li et al., 2011). In
this view, it is noteworthy that in the present work, all deaths
occurred between 2002 and 2006 (i.e. before introduction of
entecavir and tenofovir) (po0.05). This might reﬂect a global
improvement in the management of these patients, including an
earlier diagnosis and treatment, but also a more efﬁcient therapy.
Thus, none of the deceased patients had received entecavir or
tenofovir treatment.
In conclusion, we show that HBV reactivation following che-
motherapy in patients testing negative for HBsAg before che-
motherapy may occur in patients presenting with isolated anti-
HBcAb but also in those positive for anti-HBsAb. In this context,
HBV reactivation is associated with an important genetic varia-
bility of HBV strains within HBsAg and HBVrt. The emergence of
such mutated HBV strains is associated in these patients with
impaired serological diagnosis of HBV reactivation as well as an
increased risk of emergence of HBV strains resistant to antiviral
drugs. These data strongly support the use of HBV DNA detection
in the management of these patients before and during che-
motherapy and the use of antiviral drugs with a high genetic
barrier to resistance in case of HBV reactivation.
Material and methods
Patients
From July 2002 through December 2010, 22 cases of HBV-
related acute hepatitis in a context of polychemotherapy were
recorded in Marseille university hospitals. In 4 cases, HBV serolo-
gical status before initiation of anticancer treatment was not
known. In 2 cases, the patients were known to be HBsAg-
positive and HBV-related acute hepatitis occurred in the absence
of preemptive antiviral treatment (one case) or after interruption
of anti-HBV therapy (one case). In the remaining 16 cases, HBV
serological status at time of initiation of chemotherapy was
indicative of past-HBV infection, i.e. showed anti-HBc antibody-
positivity but HBsAg-negativity, with or without anti-HBsAb.
These 16 patients were selected for the study (Tables 1 and 2).
The research was conducted on plasma samples collected at the
time of diagnosis of HBV reactivation. Nine of these patients were
previously partially described (Borentain et al., 2010; Gérolami
et al., 2005, 2007). For comparative analysis of virological patterns
including HBsAg and RT regions, a control group consisting of 123
individuals with newly diagnosed chronic HBV infection over a 12-
month period (May 2003–April 2004) was used. Serum samples
had been obtained at diagnosis, before any antiviral treatment
initiation and HBV sequences have been obtained from 51 of them;
among these sequences, 26, 2, 18 and 5 belonged to genotypes A,
C, D and E, respectively (Table 1) (Colson et al., 2007).
HBV serological tests and HBV DNA detection
HBV serological markers (HBsAg, anti-HBcAb, and anti-HBsAb
(analytical threshold, 10 IU/L)) and anti-HCV antibodies were
tested using Axsym Abbott assays (Abbott Diagnostics Division,
Wiesbaden, Germany). When possible a second test (Vidas, Bio-
Mérieux, Meylan, France) was used for HBsAg determination.
Serum HBV DNA determination used the Cobas Ampliprep/Cobas
TaqMan assay, the Roche real-time assay (Roche Diagnostics,
Meylan, France; detection threshold of 6–30 IU/mL), or the Abbott
RealTime assay (Abbott Diagnostics Division, Wiesbaden, Ger-
many; detection threshold of 10 IU/mL).
HBV genotypic and amino acid patterns
Nucleic acid extraction and puriﬁcation, PCR ampliﬁcation and DNA
sequencing
Whole blood was collected in dry tubes with gel separator.
Ampliﬁcation and direct sequencing of the full-length HBsAg
coding-region and the entire RT gene were performed using in-
house protocols as previously described (Colson et al., 2007).
Sequencing was performed with the BigDye Terminator Cycle
sequencing kit v1.1 (Applied-Biosystems, Branchburg, NJ, USA) on
the ABI Prism 3130 genetic analyzer (Applied-Biosystems). Nucleo-
tide sequences were aligned using Seqscape software v2.5
(Applied-Biosystems) then compared with a set of sequences
available in GenBank for genotype determination using the MEGA
software (Kumar et al., 1994).
Analysis of amino acid substitutions within HBsAg and reverse
transcriptase
The nucleotide HBsAg/RT sequences obtained were translated
into amino acid sequences, aligned and compared with HBV
sequences of the same genotype found in the genotyping refer-
ence set available on the NCBI website (URL: http://www.ncbi.nih.
gov/projects/genotyping/view.cgi?db=2). A list of HBsAg amino
acid substitution described as affecting the recognition of HBsAg
by anti-HBsAb was obtained from the Geno2pheno [hbv] 2.0 web-
site of the Max-Planck-Institut für Informatik (URL: http://hbv.
geno2pheno.org/index.php).
Amino acid variability was deﬁned as the proportion, at each
position, of sequences that did not harbor the amino acid found in
HBV reference sequences of the same genotype. For analysis,
HBsAg was divided into sub-regions corresponding to structural
and/or functional domains: the N terminal region (amino acid 1–
99), the major hydrophilic region (MHR; amino acid 100–169) that
includes the «a» determinant (amino acid 124–147) spanning
HBsAg sub-regions 3 and 4, and the C terminal region (amino
acid 170–226) (Cooreman et al., 2001; Lin et al., 2001). HBV
genotypic patterns from patients presenting HBV reactivation
were compared to those obtained from 51 newly diagnosed HBV
carriers.
Analysis of N-linked glycosylation sites
N-linked glycosylation sites were predicted along the full-
length HBsAg amino acid sequences obtained from the 16 patients
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with HBV-R using the N-glycosite tool that is available online
through the Los Alamos National Laboratory website (URL: http://
www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html)
and detects Nx[ST] patterns (where N¼asparagine, S¼serine, T¼
threonine and x can be any amino acid apart from proline) (Zhang
et al., 2004).
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